PDS Biotechnology Corporation
PDSB
$1.26
$0.021.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.99% | -7.61% | 5.05% | 20.76% | 24.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.62% | -23.50% | -17.65% | 2.59% | 3.29% |
| Operating Income | 15.62% | 23.50% | 17.65% | -2.59% | -3.29% |
| Income Before Tax | 13.23% | 21.23% | 15.49% | -4.74% | -5.46% |
| Income Tax Expenses | 38.18% | 38.18% | 38.18% | -17.27% | -17.27% |
| Earnings from Continuing Operations | 12.42% | 20.76% | 14.82% | -4.39% | -5.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.42% | 20.76% | 14.82% | -4.39% | -5.11% |
| EBIT | 15.62% | 23.50% | 17.65% | -2.59% | -3.29% |
| EBITDA | 15.65% | 23.53% | 17.64% | -2.61% | -3.28% |
| EPS Basic | 25.38% | 31.43% | 23.90% | 4.69% | 4.23% |
| Normalized Basic EPS | 26.11% | 31.87% | 24.57% | 4.33% | 3.88% |
| EPS Diluted | 25.38% | 31.55% | 24.05% | 4.91% | 4.44% |
| Normalized Diluted EPS | 26.11% | 31.87% | 24.57% | 4.33% | 3.88% |
| Average Basic Shares Outstanding | 17.77% | 15.51% | 12.93% | 10.15% | 10.43% |
| Average Diluted Shares Outstanding | 17.77% | 15.51% | 12.93% | 10.15% | 10.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |